Diabesity Rounds
Today / Sunday Rounds

Protecting lean mass on incretins: exercise and trevogrumab both cut loss

Resistance exercise with tirzepatide and trevogrumab with semaglutide each reduced lean mass loss in randomised trials. Only the exercise trial reported strength, and the antibody combination had unfavourable safety and tolerability.

At a glance

  • Resistance exercise with tirzepatide reduced loss of total lean soft tissue mass (-3.57 kg versus -4.67 kg), and strength rose instead of falling.
  • Trevogrumab with semaglutide reduced lean mass loss at 200 mg, 400 mg and 75 mg, but not at 25 mg. The garetosmab combination had a high incidence of serious adverse events and discontinuations.
  • The two trials cannot be compared directly. Neither report gives falls, fractures, disability or other clinical outcomes.

This week's question

Weight loss with GLP-1-based drugs is not only fat loss. Both trials this week address the loss of lean or muscle mass during incretin-based weight loss. The question is how to limit that loss.

The authors of the exercise trial note that lower lean soft tissue mass may impair skeletal muscle function. The COURAGE authors say further study is needed to learn whether better body composition preserves function and metabolic health.

The two trials test very different answers. One adds a structured resistance exercise programme to tirzepatide. The other adds antibodies that block myostatin (GDF8) and activin A to semaglutide. Neither report describes results in Indian patients. COURAGE was US-based and its abstract gives no results by ethnicity.

What the studies showed

Resistance exercise with tirzepatide. The resistance exercise trial report describes a two-arm randomised trial in Nature Medicine. A total of 120 adults with overweight or obesity took tirzepatide. They were randomised to thrice-weekly resistance exercise or usual activities for 40 weeks. Adherence to exercise was 91%.

  • Weight loss was similar: -22.61 kg with tirzepatide alone and -22.28 kg with exercise added (P = 0.694).
  • Fat mass loss was similar: -17.19 kg and -17.98 kg (P = 0.700).
  • Total lean soft tissue mass fell less with exercise: -4.67 kg with tirzepatide alone and -3.57 kg with exercise (P < 0.001). The between-group difference was 1.09 kg (95% CI 0.43-1.75 kg).
  • Strength fell with tirzepatide alone (bench press -4.09 kg, lat pulldown -4.42 kg, knee extension -4.42 kg). It rose with exercise (+4.68 kg, +8.58 kg, +5.88 kg). All differences versus tirzepatide alone had P < 0.001.

Trevogrumab with semaglutide. The COURAGE trial report describes a two-part, phase 2, double-blind, placebo-controlled trial of 975 adults with obesity at 60 US sites. It was funded by Regeneron Pharmaceuticals, Inc.

In part A (26 weeks), lean mass fell by 6.6% with semaglutide plus placebo. The estimated differences versus placebo were +3.1% for trevogrumab 200 mg, +2.7% for 400 mg, and +4.5% for 400 mg plus garetosmab.

In part B (52 weeks), lean mass fell by 7.3% with placebo. Trevogrumab 75 mg gave a difference of +3.1% (95% CI 1.3 to 4.9). Trevogrumab 25 mg gave +1.5% (95% CI -0.3 to 3.3), which was not significantly different from placebo.

Fat mass and bodyweight need separate mention. In part A, fat mass fell by 15.6% with placebo. The estimated treatment difference was significant for trevogrumab 400 mg (-3.4%) and for the combination (-11.7%). Bodyweight fell by 10.6% with placebo, and the difference was significant only for the combination (-2.7). No part B group differed significantly from placebo for fat mass or bodyweight.

Semaglutide plus trevogrumab alone was generally well tolerated, with a safety profile similar to semaglutide plus placebo. In the combination group, serious adverse events occurred in 14 (9%) of 149 participants and discontinuations in 48 (32%) of 149. Muscle spasms occurred in 61 (41%) of 149 in the combination group, 23 (8%) of 299 in the trevogrumab 200 mg and 400 mg groups, and seven (5%) of 151 on placebo. Both deaths in the study were in the combination group. A causal association with treatment was not identified.

Where they agree and where they do not

Both randomised trials found that the add-on reduced the fall in lean mass during incretin-based weight loss. Both used surrogate measures, and neither report gives hard clinical outcomes.

They differ in important ways, and they should not be compared head to head:

  • Drug: tirzepatide in one, semaglutide in the other.
  • Comparator: usual activities in the exercise trial, placebo in a double-blind design in COURAGE.
  • Duration: 40 weeks, versus 26 weeks (part A) and 52 weeks (part B).
  • Units: kilograms in the exercise trial, percent change in COURAGE.
  • Population: the exercise trial included adults with overweight or obesity. COURAGE enrolled adults with obesity (BMI 30 kg/m2 or more) in the US.

The two reports also differ on function. The exercise trial measured strength, and it rose with exercise. The COURAGE report does not give physical function results.

They differ on safety evidence too. The exercise trial authors report that tirzepatide was safe, but the abstract gives no adverse event details. COURAGE reported a high incidence of serious adverse events and discontinuations in the combination group, and more muscle spasms there than in the other groups. The authors say the combination did not have favourable safety and tolerability. Serious adverse event and discontinuation rates are given only for the combination group, so they cannot be compared with the other groups.

The fat and weight results also differ. In the exercise trial, there was no significant difference in weight or fat mass loss. In COURAGE part A, fat mass loss was significantly greater with trevogrumab 400 mg and with the combination. Bodyweight differed significantly only with the combination.

What is still unknown

  • Whether less lean mass loss means better function, fewer falls or fractures, or less disability. Neither report gives these outcomes.
  • Whether the 1.09 kg difference in lean soft tissue mass matters clinically. The exercise report says this is not shown.
  • What happens to lean mass and strength after the 40 weeks, or after tirzepatide is stopped. The exercise report does not say.
  • How the exercise programme was delivered and supervised, and what it needed. The abstract does not describe this. It also does not report funding, blinding, drop-outs, or participant age, sex and diabetes status.
  • How lean mass was measured in COURAGE, and the results of its withdrawal period and MRI thigh substudy. These are not reported in the abstract.
  • Whether results differ by ethnicity. The COURAGE abstract gives no results by ethnicity, and neither report describes results in Indian patients.
  • Whether the safety and tolerability problems with the garetosmab combination can be explained or avoided. The report does not say.

For your clinic on Monday

The exercise trial gives the more usable message. In adults on tirzepatide, a structured resistance exercise programme reduced lean soft tissue loss and improved strength, with no significant difference in weight or fat mass loss. This supports discussing resistance exercise as part of obesity care alongside drug treatment. Exercise advice for any individual patient should take into account their other conditions and physical fitness.

The antibody results are early. The authors describe trevogrumab alone as a proof of concept from a phase 2 trial. Whether better body composition helps patients in daily life is not yet shown. The garetosmab combination did not have favourable safety and tolerability.

For both trials, read the full paper before drawing conclusions. Check who was enrolled, how lean mass was measured, and what safety data were reported. Wait for trials with functional outcomes.

Sources

Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.

Mosenzon O, Rosenstock J, Raya JG et al.. Lancet (London, England). 11 November 2026

Read the source · DOI 10.1016/S0140-6736(26)01953-7

Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial.

Green DJ, Haynes A, Underwood DR et al.. Nature medicine. 9 November 2026

Read the source · DOI 10.1038/s41591-026-04752-5

Cite this piece: Diabesity Rounds. Protecting lean mass on incretins: exercise and trevogrumab both cut loss. 2026. doi:10.5281/zenodo.24272070

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on obesity medicine

Go deeper